Carbylan BioSurgery Inc., a Palo Alto, Calif.-based developer of bioresponsive devices for osteoarthritis and chronic rhinosinusitis, has raised $20 million in Series B funding.Vivo Ventures led the deal, and was joined by return backers Alta Partners and InterWest Partners.Carbylan raised a $7.9 million Series A round in late 2005.
26 Nov 2007
